Valerius T - Search Results

1

Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.

Peipp M, Dechant M, Valerius T. Peipp M, et al. Among authors: valerius t. MAbs. 2009 Nov-Dec;1(6):590-9. doi: 10.4161/mabs.1.6.10051. Epub 2009 Nov 11. MAbs. 2009. PMID: 20068398 Free PMC article. Review.

2

Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.

Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, Valerius T, Keler T, Tutt AL, Glennie MJ, van Royen EA, Capel PJ, van de Winkel JG. Heijnen IA, et al. Among authors: valerius t. J Immunol. 1997 Dec 1;159(11):5629-39. J Immunol. 1997. PMID: 9548506

3

Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M, Gramatzki M. Würflein D, et al. Among authors: valerius t. Cancer Res. 1998 Jul 15;58(14):3051-8. Cancer Res. 1998. PMID: 9679970

4

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T. Stockmeyer B, et al. Among authors: valerius t. J Immunol. 2000 Nov 15;165(10):5954-61. doi: 10.4049/jimmunol.165.10.5954. J Immunol. 2000. PMID: 11067958

5

Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.

Stockmeyer B, Elsässer D, Dechant M, Repp R, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T. Stockmeyer B, et al. Among authors: valerius t. J Immunol Methods. 2001 Feb 1;248(1-2):103-11. doi: 10.1016/s0022-1759(00)00346-x. J Immunol Methods. 2001. PMID: 11223072

6

IgA antibodies for cancer therapy.

Dechant M, Valerius T. Dechant M, et al. Among authors: valerius t. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):69-77. doi: 10.1016/s1040-8428(01)00105-6. Crit Rev Oncol Hematol. 2001. PMID: 11418303 Review.

7

Bispecific antibodies targeting cancer cells.

Peipp M, Valerius T. Peipp M, et al. Among authors: valerius t. Biochem Soc Trans. 2002 Aug;30(4):507-11. doi: 10.1042/bst0300507. Biochem Soc Trans. 2002. PMID: 12196124 Review.

8

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.

Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van De Winkel JG, Valerius T. Dechant M, et al. Among authors: valerius t. Blood. 2002 Dec 15;100(13):4574-80. doi: 10.1182/blood-2002-03-0687. Epub 2002 Aug 8. Blood. 2002. PMID: 12393717 Free article.

9

HLA class II antibodies in the treatment of hematologic malignancies.

Dechant M, Bruenke J, Valerius T. Dechant M, et al. Among authors: valerius t. Semin Oncol. 2003 Aug;30(4):465-75. doi: 10.1016/s0093-7754(03)00252-5. Semin Oncol. 2003. PMID: 12939715 Review.

10

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.

Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, Titgemeyer F, Niederweis M, Peipp M, Zunino SJ, Repp R, Valerius T, Fey GH. Bruenke J, et al. Among authors: valerius t. Br J Haematol. 2004 Apr;125(2):167-79. doi: 10.1111/j.1365-2141.2004.04893.x. Br J Haematol. 2004. PMID: 15059139 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters